Brain-wide insulin resistance, tau phosphorylation changes, and hippocampal neprilysin and amyloid-β alterations in a monkey model of type 1 diabetes

Journal of Neuroscience

Volumn 36, Issue 15, 2016, Pages 4248-4258

  Morales Corraliza, Jose ^a,b   Wong, Harrison ^a   Mazzella, Matthew J ^a   Che, Shaoli ^a,b   Lee, Sang Han ^a   Petkova, Eva ^a,b   Wagner, Janice D ^c   Hemby, Scott E ^d   Ginsberg, Stephen D ^a,b   Mathews, Paul M ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d HIGH POINT UNIVERSITY   (United States)

Author keywords

Alzheimer s disease; Diabetes; Hippocampus; Neprilysin; Nonhuman primate; Streptozotocin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CALCINEURIN; CYCLIN DEPENDENT KINASE 5; ENDOTHELIN CONVERTING ENZYME; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HEMOGLOBIN A1C; INSULIN RECEPTOR SUBSTRATE 1; INSULINASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P25; PROTEIN P35; TAU PROTEIN; AMYLOID BETA PROTEIN;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BRAIN FUNCTION; CEREBELLUM; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL CORTEX; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HYPERGLYCEMIA; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MALE; MEMBRANE TRANSPORT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TEMPORAL CORTEX; WESTERN BLOTTING; ANIMAL; BRAIN CHEMISTRY; EXPERIMENTAL DIABETES MELLITUS; LIVER; METABOLISM; PHOSPHORYLATION;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN CHEMISTRY; CERCOPITHECUS AETHIOPS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HIPPOCAMPUS; INSULIN RESISTANCE; LIVER; MALE; NEPRILYSIN; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84963780554     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4640-14.2016     Document Type: Article

References (81)

1. Agresti A (2007) An introduction to categorical data analysis, Ed 2. New York: Wiley.
2. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63:1551–1555.CrossRef Medline
3. Alldred MJ, Che S, Ginsberg SD (2009) Terminal continuation (TC) RNA amplification without second strand synthesis. J Neurosci Methods 177: 381–385.CrossRef Medline
4. Alldred MJ, Duff KE, Ginsberg SD (2012) Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis 45:751–762.CrossRef Medline
5. Biessels GJ, Reagan LP (2015) Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci 16:660–671.CrossRef Medline
6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5: 64–74.CrossRef Medline
7. Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–278; discussion 278–284. Medline
8. Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223–234.CrossRef Medline
9. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130.CrossRef Medline
10. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders. Neurobiol Aging 26:645-654.CrossRef Medline
11. Chang AY, Schneider DI (1971) Hepatic enzyme activities in streptozotocin- diabetic rats before and after insulin treatment. Diabetes 20: 71–77.CrossRef Medline
12. Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, Liu F, Gong CX (2014a) Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 261:610–619.CrossRef Medline
13. Chen Y, Run X, Liang Z, Zhao Y, Dai CL, Iqbal K, Liu F, Gong CX (2014b) Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. Front Aging Neurosci 6:100.CrossRef Medline
14. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis [Erratum (2015) 45:1269-1270] 44:897–906.CrossRef Medline
15. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29-38.CrossRef Medline
16. de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol 88:548-559.CrossRef Medline
17. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates β-amyloid peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907–913.CrossRef Medline
18. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of β-amyloid peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 8:16-30.CrossRef Medline
19. De Felice FG, Lourenco MV (2015) Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer’s disease. Front Aging Neurosci 7:94.CrossRef Medline
20. DeFronzo RA (2004) Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 88:787-835, ix. Medline
21. Devi L, Alldred MJ, Ginsberg SD, Ohno M (2012) Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s disease. PLoS One 7:e32792.CrossRef Medline
22. Drewes G, Lichtenberg-Kraag B, Döring F, Mandelkow EM, Biernat J, Goris J, Dorée M, Mandelkow E (1992) Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 11: 2131–2138.Medline
23. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer’s β-amyloid peptide by endothelin- converting enzyme. J Biol Chem 276: 24540–24548.CrossRef Medline
24. El Khoury NB, Gratuze M, Papon MA, Bretteville A, Planel E (2014) Insulin dysfunction and Tau pathology. Front Cell Neurosci 8:22.CrossRef Medline
25. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, β-amyloid protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100:4162-4167.CrossRef Medline
26. Farris W, Schu¨tz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ (2007) Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171:241–251.CrossRef Medline
27. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113:1753–1759.CrossRef Medline
28. Garcíia-Casares N, Jorge RE, García-Arnés JA, Acion L, Berthier ML, Gonzalez-Alegre P, Nabrozidis A, Gutiérrez A, Ariza MJ, Rioja J, González-Santos P (2014) Cognitive dysfunctions in middle-aged type 2 diabetic patients and neuroimaging correlations: a cross-sectional study. J Alzheimers Dis 42:1337–1346.CrossRef Medline
29. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B (2004) Systemic catabolism of Alzheimer’s Aβ40 and Aβ42. J Biol Chem 279:45897-45908.CrossRef Medline
30. Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, Che S (2010) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol Psychiatry 68:885-893.CrossRef Medline
31. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science 293:1491–1495.CrossRef Medline
32. Greenbaum CJ (2002) Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 18:192–200.CrossRef Medline
33. Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99-109.CrossRef Medline
34. Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L (2010) Transsynaptic progression of β-amyloid-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68:428–441.CrossRef Medline
35. Hellström-Lindahl E, Ravid R, Nordberg A (2008) Age-dependent decline of neprilysin in Alzheimer’s disease and normal brain: inverse correlation with Aβ levels. Neurobiol Aging 29:210-221.CrossRef Medline
36. Hölscher C (2014) First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer’s disease. Alzheimers Dement 10:S33–S37.CrossRef Medline
37. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:143–150.CrossRef Medline
38. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292:1550–1552.CrossRef Medline
39. Johnson GD, Stevenson T, Ahn K (1999) Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem 274:4053-4058.CrossRef Medline
40. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E (2010) Type 1 diabetes exaggerates features of Alzheimer’s disease in APP transgenic mice. Exp Neurol 223:422-431.CrossRef Medline
41. Jung HJ, Kim YJ, Eggert S, Chung KC, Choi KS, Park SA (2013) Agedependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. Exp Neurol 248: 441–450.CrossRef Medline
42. Kavanagh K, Flynn DM, Nelson C, Zhang L, Wagner JD (2011) Characterization and validation of a streptozotocin-induced diabetes model in the vervet monkey. J Pharmacol Toxicol Methods 63:296-303.CrossRef Medline
43. Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer’s disease. PLoS One 4:e7917.CrossRef Medline
44. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T (1996) Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 7:177–181.Medline
45. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487–1491.CrossRef Medline
46. Li J, Deng J, Sheng W, Zuo Z (2012) Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101:564-574.CrossRef Medline
47. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease. J Neurochem 111:242–249.CrossRef Medline
48. Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA (2002) Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of β-cleaved C-terminal APP fragments. J Biol Chem 277:36415–36424.CrossRef Medline
49. McCrimmon RJ, Sherwin RS (2010) Hypoglycemia in type 1 diabetes. Diabetes 59:2333–2339.CrossRef Medline
50. McCrimmon RJ, Ryan CM, Frier BM (2012) Diabetes and cognitive dysfunction. Lancet 379:2291–2299.CrossRef Medline
51. Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224-243.CrossRef Medline
52. Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, Matsuoka Y, Planel E, Mathews PM (2009) In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the β-amyloid depositing mice. PLoS One 4:e7134.CrossRef Medline
53. Morales-Corraliza J, Schmidt SD, Mazzella MJ, Berger JD, Wilson DA, Wesson DW, Jucker M, Levy E, Nixon RA, Mathews PM (2013) Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer’s disease mouse model. Neurobiol Aging 34:137–145.CrossRef Medline
54. Needham BE, Wlodek ME, Ciccotosto GD, Fam BC, Masters CL, Proietto J, Andrikopoulos S, Cappai R (2008) Identification of the Alzheimer’s disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J Pathol 215:155–163.CrossRef Medline
55. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y (2006) BACE1 inhibition reduces endogenous Aβ and alters APP processing in wild-type mice. J Neurochem 99:1555–1563.CrossRef Medline
56. Noöl A, Poitras I, Julien J, Petry FR, Morin F, Charron J, Planel E (2015) ERK (MAPK) does not phosphorylate tau under physiological conditions in vivo or in vitro. Neurobiol Aging 36:901–902.CrossRef Medline
57. Papon MA, El Khoury NB, Marcouiller F, Julien C, Morin F, Bretteville A, Petry FR, Gaudreau S, Amrani A, Mathews PM, Hébert SS, Planel E (2013) Deregulation of protein phosphatase 2A and hyperphosphorylation of tau protein following onset of diabetes in NOD mice. Diabetes 62:609–617.CrossRef Medline
58. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27:13635–13648.CrossRef Medline
59. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels ofβ-amyloid protein by degradation. J Biol Chem 273:32730-32738.CrossRef Medline
60. Rdzak GM, Abdelghany O (2014) Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer’s disease? Pharmacotherapy 34: 1317–1323.CrossRef Medline
61. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3β. J Neurochem 74:1587–1595.Medline
62. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24-26.CrossRef Medline
63. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clearance of β-amyloid by circulating lipoprotein receptors. Nat Med 13:1029-1031.CrossRef Medline
64. Saisho Y, Manesso E, Butler AE, Galasso R, Kavanagh K, Flynn M, Zhang L, Clark P, Gurlo T, Toffolo GM, Cobelli C, Wagner JD, Butler PC (2011) Ongoing β-cell turnover in adult nonhuman primates is not adaptively increased in streptozotocin-induced diabetes. Diabetes 60:848–856.CrossRef Medline
65. Schmidt SD, Nixon RA, Mathews PM (2012a) Tissue processing prior to analysis of Alzheimer’s disease associated proteins and metabolites, including Aβ. Methods Mol Biol 849:493–506.CrossRef Medline
66. Schmidt SD, Mazzella MJ, Nixon RA, Mathews PM (2012b) Aβ measurement by enzyme-linked immunosorbent assay. Methods Mol Biol 849: 507–527.CrossRef Medline
67. Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6:551–559.CrossRef Medline
68. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del- Favero J, Cruts M, van Duijn CM, Van Broeckhoven C (2006) APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain 129:2977–2983.CrossRef Medline
69. Soleilhac JM, Lafuma C, Porcher JM, Auburtin G, Roques BP (1996) Characterization of a soluble form of neutral endopeptidase-24.11 (EC 3.4.24.11) in human serum: enhancement of its activity in serum of underground miners exposed to coal dust particles. Eur J Clin Invest 26: 1011–1017.CrossRef Medline
70. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM, Grant PJ (2011) Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 35:1031–1040.CrossRef Medline
71. Szendrei GI, Lee VM, Otvos L Jr (1993) Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J Neurosci Res 34:243–249.CrossRef Medline
72. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R (2010) Diabetesaccelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107:7036-7041.CrossRef Medline
73. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:1316-1338.CrossRef Medline
74. Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, Peters EC, Urbina HD, Welzel G, Althage A, Liu B, Tuntland T, Jacobson LH, Harris JL, Schumacher AM (2013) Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. J Neurosci 33:2457–2464.CrossRef Medline
75. Wang Q, Zhou Y, Wang X, Evers BM (2006) Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 25:43–50.CrossRef Medline
76. Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS (2010) Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer’s brain. J Neurochem 115:47–57.CrossRef Medline
77. Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging 21:719-727.CrossRef Medline
78. White MF (2006) Regulating insulin signaling and β-cell function through IRS proteins. Can J Physiol Pharmacol 84:725–737.CrossRef Medline
79. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643-651.CrossRef Medline
80. Yarchoan M, Arnold SE (2014) Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 63:2253–2261.CrossRef Medline
81. Yasojima K, Akiyama H, McGeer EG, McGeer PL (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci Lett 297:97–100.CrossRef Medline